The Griffith Family Foundation has donated from 2010 to date over $200,000 to the research efforts of Dr. A. James Moser MD FACS, Co-Director, Pancreas and Liver Institute Beth Israel Deaconess Medical Center.
On October 27, Dr. Moser and Dr. Niven R. Narain, Co-founder, President and CEO, Berg, will be participating in a forum called “Early Detection of Pancreatic Cancer: The Role of Industry in the Development of Biomarkers” presented by the Kenner Family Research Fund (KFRF) in Partnership with the American Pancreatic Association (APA).
This forum is part of the strategic plan initially set forth at the 2014 Early Detection of Sporadic Pancreatic Cancer Summit Conference presented by KFRF also in partnership with the APA, which provided a foundation for the field (“Early Detection of Sporadic Pancreatic Cancer: Summative Review”).
Presentations during the forum will include:
- “Current State of Biomarkers” by Sudhir Srivastava, PhD, PMH, MS, Chief, Cancer Biomarkers Research Group National Cancer Institute
- “GRAIL” by Anne-Renee Hartman, MD, Medical Director and Director of Clinical Product Development
- “Immunovia” by Christer Wingren, PhD, Chief Technology Officer; and Laura Chirica, PhD, Chief Commercial Officer
- “Project Survival” by Niven R. Narain, MD, Co-founder, President and CEO, Berg; and A. James Moser, MD FACS, Co-Director, Pancreas and Liver Institute Beth Israel Deaconess Medical Center
Following the presentations, a conversation between the distinguished panelists and the audience will be facilitated by Suresh T. Chari, MD, Director of the Pancreas Clinic at Mayo Clinic and Anirban Maitra, MBBS, Scientific Director of the Sheikh Ahmed Bin Zayed Center for Pancreas Cancer Research at MD Anderson Cancer Center.